-
These results of the distinct presence of NPRA and NPRBpositive cells in unstable plaques underlying acute myocardial infarction suggested that natriuretic peptides serve a role in regulating plaque instability in humans.
-
Atenolol treatment normalized the altered expression of Npr1 and Npr2 genes.
-
Data suggest mutations in NPR2 in patients with skeletal overgrowth alter conformation: A488P/R655C missense mutations yield conformation mimicking allosterically activated NPR2; A488P mutation sets phosphorylation as requirement for CNP-dependent activation; R655C mutation abrogates need for phosphorylation; ATP analog inhibits mutants. (NPR2 = atrial natriuretic factor receptor B; CNP = C-type natriuretic peptide)
-
in 4 Indian families with acromesomelic dysplasia, type Maroteaux, 4 homozygous mutations in four different families were identified; these include 3 novel mutations including a deletion frameshift mutation (p.Cys586Ter), one nonsense mutation (p.Arg479Ter), one missense mutation (p.Val187Asp) and one reported missense mutation (p.Tyr338Cys)
-
Heterozygous mutation in NPR2 gene is associated with short stature.
-
Mutations in three genes (GDF5, NPR2, BMPR1B) have been reported to cause different forms of acromesomelic dysplasia
-
IL1R2 hypomethylation and androgen receptor hypermethylation may constitute an important determinant of disease severity, whereas NPR2 hypomethylation and SP140 hypermethylation may provide a biomarker for vulnerability to excessive daytime sleepiness in Obstructive Sleep Apnea
-
Loss-of-function mutations of the NPR2 gene is associated with acromesomelic dysplasia, type maroteaux.
-
Heterozygous mutations in natriuretic peptide receptor-B (NPR2) gene as a cause of short stature
-
NPR2 mutations account for approximately 3% of patients with disproportionate short stature and/or clinical or radiographic indicators of SHOX deficiency and in whom no SHOX defect has been identified.
-
3 consanguineous families segregating Acromesomelic dysplasia Maroteaux type in an autosomal recessive manner studied. Linkage in the families was established to the NPR2 gene on chromosome 9p12-21. Sequence analysis revealed 2 novel missense variants (p.Arg601Ser; p.Arg749Trp) in 2 families and a previously reported splice site variant (c.2986+2T>G) in the third family.
-
Cardiac fibrosis and the endogenous natriuretic peptide system were evaluated in end-stage heart failure to assess the anti-fibrotic actions of the dual GC-A/-B activator.
-
Overgrowth syndrome associated with a gain-of-function mutation of the natriuretic peptide receptor 2 (NPR2) gene.
-
Gene expression of C-type natriuretic peptide and of its specific receptor NPR-B in human leukocytes of healthy and heart failure subjects
-
Molecular dynamics analysis indicated decreases in the values of Van der Waals, electrostatic energy and potential energy of NPRB/Vasonatrin peptide compared to NPRA/Vasonatrin peptide.
-
Identification of heterozygous dominant negative NPR2 mutations in 2% of Japanese patients with short stature.
-
KIdney NPR2 protein quantity is significantly impacted by genetic variation.
-
study concludes V883M mutation increases maximal velocity in absence of C-type natriuretic peptide (CNP), eliminates requirement for ATP in the CNP-dependent Km reduction and disrupts normal inactivation process; established a molecular mechanism for how an amino acid substitution in GC-B activates the enzyme, which results in abnormally long and fragile bones
-
In transgenic mice, complete absence of Npr2 activity prohibits the bifurcation of cranial sensory axons.
-
Although no novel phosphorylation sites that influenced the suppression of guanylate cyclase-B were identified, experiments revealed that mutations in Tyr808 markedly enhanced GC-B activity.
